Drugs / BL-M14D1
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07080242 | Apr 2025 → Dec 2027 expected | cutaneous neuroendocrine carcinoma, prostate neuroendocrine neoplasm, pulmonary large cell neuroendocrine carcinoma, small cell lung carcinoma | SystImmune Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06505824 | Aug 2024 → Aug 2026 overdue | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07654400 | Jul 2026 → Dec 2027 expected | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07625644 | Jun 2026 → Jan 2030 expected | small cell lung carcinoma | SystImmune Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-M14D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06505824 ↗ |
| Route | Intravenous | “as intravenous infusion” NCT06505824 ↗ |